Take­da adds one more late-stage treat­ment to its grow­ing ros­ter of celi­ac drugs

What­ev­er hap­pens with Take­da’s de­ter­mined cam­paign to tack­le celi­ac dis­ease from all sides, no one will ever be able to fault them for a lack of ded­i­ca­tion to the cause.

This morn­ing, the glob­al play­er joined hands with Zedi­ra and Dr. Falk Phar­ma GmbH on a Phase IIb celi­ac drug dubbed ZED1227/TAK-227, giv­ing Take­da dibs on the big US mar­ket plus a string of coun­tries out­side Eu­rope.

Take­da, though, is any­thing but a new­com­er when it comes to fight­ing gluten in­tol­er­ance, a food al­ler­gy that cur­rent­ly can on­ly be treat­ed with a strict di­et that avoids all wheat, bar­ley and rye. The com­pa­ny has inked a range of al­liances to build up a pipeline of a well-ad­vanced set of drugs for celi­ac.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.